Which of these two small-cap gene-editing stocks is a better investment?
News & Analysis: Intellia Therapeutics
These two gene-editing stocks have a lot going for them. Let's consider pipelines, partnerships, and profits to make a choice.
Preclinical results from two of the biotech's pipeline candidates look promising.
What's expected to be a busy year for CRISPR stocks started off with a thud, not a bang.
Its CRISPR technology has the potential to cure certain genetic diseases, but investors who buy in now will require patience.
More pipeline activity than ever before could usher in a big boom for CRISPR gene-editing stocks next year.
An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
Here's why 2020's going to be a big year for three gene-editing stocks.
The industry's most advanced drug candidate based on CRISPR gene editing has data from the first two patients.
Which stock wins in a matchup between these two gene-editing pioneers?